Additionally, IRE1α-XBP1 signaling is essential for NSCLC progression, and ablation of IRE1α-XBP1 signaling extends survival in vivo by eliciting adaptive anti-cancer immunity [36]. The gene discussed is XBP1; the disease is non-small cell lung carcinoma.